Repligen | RGEN - 税前利润



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 606.78M
销售成本
USD 94.09M
流动资产
USD 1.2B
流动负债
USD 132.66M
债务
USD 690.94M
EBIT
USD 21.13M
EBITDA
USD 43.77M
员工
1.78K
EPS每股收益
USD 0.54
股本和储备
USD 2.11B
销售毛利
USD 110.04M
债务利息支出
USD 5.66M
利息收入
USD 7.31M
贷款资金
USD 551.05M
市值
USD 9.27B
净收入
USD 5.01M
营业费用
USD 183M
营业利润
USD 21.13M
普通股股本
USD 56.43M
PE价格收益
105.09
税前利润
USD 14.15M
销售收入
USD 204M
销售和管理费用
USD 76.62M
股票
USD 186.6M
贸易债权人
USD 33.23M
应收帐款人
USD 157.71M


税前利润 更改 日
Agilent USD 364M 78M 2025-12
Align Technology USD 148.69M 193K 2026-06
Bio Techne USD 106.09M 34.87M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Bruker USD 117M 95.1M 2026-06
Charles River Laboratories USD -29.94M 264.16M 2026-03
Danaher USD 1.08B 157M 2026-06
Dentsply International USD -42M 105M 2026-03
General Electric Aerospace USD 2.2B 654M 2026-03
Henry Schein USD 137M 13M 2026-06
Illumina USD 260M 103M 2026-06
IQVIA Holdings USD 301M 5.92B 2026-06
Mettler Toledo International USD 209.66M 119.42M 2026-03
Myriad Genetics USD 4.6M 3.4M 2025-12
OraSure Technologies USD -18.43M 5.14M 2025-12
Pacific Biosciences Of California USD -40.17M 2.55M 2025-12
Pfizer USD -653M 5.84B 2026-06
Repligen USD 14.15M 12.38M 2026-06
Revvity USD 187.24M 137.25M 2026-06
Standard Biotools USD -14.62M 7.42M 2026-03
Thermo Fisher Scientific USD 1.73B 389M 2026-03
Waters USD 356M 444M 2026-06
West Pharmaceutical Services USD 180.1M 18.6M 2026-03